keyword
MENU ▼
Read by QxMD icon Read
search

Intravitreal implant

keyword
https://www.readbyqxmd.com/read/28228411/retinal-vascular-calibre-changes-after-intravitreal-bevacizumab-or-dexamethasone-implant-treatment-for-diabetic-macular-oedema
#1
Sanjeewa S Wickremasinghe, Samantha Fraser-Bell, Elizabeth Alessandrello, Hemal Mehta, Mark C Gillies, Lyndell L Lim
PURPOSE: To compare changes in retinal vascular calibre after 2 years of treatment with intravitreal bevacizumab (BVZ) or dexamethasone implant (DEX) in patients with centre-involving diabetic macular oedema (DMO). METHODS: At baseline, 88 eyes of 61 patients with DMO were recruited in a prospective, multicentre, randomised, single-masked clinical trial. Of these subjects, 22 BVZ-treated (52%) and 22 DEX-treated (48%) eyes of 34 patients (56%) had gradable retinal photographs at both the baseline and 24-month visits...
February 22, 2017: British Journal of Ophthalmology
https://www.readbyqxmd.com/read/28224388/ocular-safety-of-intravitreal-clindamycin-hydrochloride-released-by-plga-implants
#2
Gabriella M Fernandes-Cunha, Silvia Ligório Fialho, Gisele Rodrigues da Silva, Armando Silva-Cunha, Min Zhao, Francine Behar-Cohen
BACKGROUND: Drug ocular toxicity is a field that requires attention. Clindamycin has been injected intravitreally to treat ocular toxoplasmosis, the most common cause of eye posterior segment infection worldwide. However, little is known about the toxicity of clindamycin to ocular tissues. We have previously showed non intraocular toxicity in rabbit eyes of poly(lactic-co-glycolic acid) (PLGA) implants containing clindamycin hydrochloride (CLH) using only clinical macroscotopic observation...
February 21, 2017: Pharmaceutical Research
https://www.readbyqxmd.com/read/28221257/intravitreal-dexamethasone-implant-in-retinitis-pigmentosa-related-cystoid-macular-edema
#3
Ahmad M Mansour, Huda Sheheitli, Cem Kucukerdonmez, Robert A Sisk, Raphael Moura, Marilita M Moschos, Luiz H Lima, Laila Al-Shaar, J Fernando Arevalo, Mauricio Maia, Robert E Foster, Ozcan Kayikcioglu, Igor Kozak, Shree Kurup, Hernando Zegarra, Roberto Gallego-Pinazo, Rola N Hamam, Riad A Bejjani, Esat Cinar, Ethem T Erakgün, Alan Kimura, Anderson Teixeira
PURPOSE: To report the clinical outcome after intravitreal dexamethasone implant in patients with retinitis pigmentosa and cystoid macular edema. METHODS: Multicenter retrospective case series of eyes with retinitis pigmentosa and cystoid macular edema that underwent intravitreal dexamethasone implant. Primary outcome measures were best-corrected visual acuity in LogMAR and central macular thickness. Statistical analyses used two-tailed comparison with Wilcoxon signed-rank test...
February 17, 2017: Retina
https://www.readbyqxmd.com/read/28218368/intravitreal-dexamethasone-implant-ozurdex%C3%A2-for-exudative-retinal-detachment-after-proton-beam-therapy-for-choroidal-melanoma
#4
Ariane Malclès, Anh-Minh Nguyen, Thibaud Mathis, Jean-Daniel Grange, Laurent Kodjikian
PURPOSE: To evaluate the efficacy and safety of intravitreal 0.7-mg dexamethasone implant (DEX-I) (Ozurdex®) in the treatment of extensive exudative retinal detachment (RD) associated with uveal melanoma treated using proton beam therapy (PBT). METHODS: Data from 10 patients with exudative RD after PBT treated with intravitreal injection of 0.7-mg DEX-I were reviewed retrospectively. The main outcome measures were resolution of exudative RD, visual acuity, and safety profile...
February 8, 2017: European Journal of Ophthalmology
https://www.readbyqxmd.com/read/28208166/incidence-and-visual-outcomes-of-culture-proven-endophthalmitis-following-dexamethasone-intravitreal-implant
#5
Maxwell S Stem, Bozho Todorich, Yoshihiro Yonekawa, Antonio Capone, George A Williams, Alan J Ruby
Importance: The rate of endophthalmitis following dexamethasone intravitreal implant (DEX) has varied in large clinical trials. Furthermore, to our knowledge, the optimal management of eyes with endophthalmitis associated with DEX has not been established. Objective: To report the incidence of culture-proven endophthalmitis in a single vitreoretinal practice over the course of 3 years and describe the clinical outcomes associated with each case of endophthalmitis...
February 16, 2017: JAMA Ophthalmology
https://www.readbyqxmd.com/read/28203186/real-life-iluvien-fluocinolone-acetonide-case-study-rapid-drying-of-the-macula-and-improved-vision-within-2-years-after-therapy-initiation
#6
Hibba Quhill, Fahd Quhill
IMPORTANCE: A case showing sustained structural and functional responses 2 years after a single treatment with ILUVIEN (0.2 µg/day fluocinolone acetonide, FAc) despite suboptimal responses to ranibizumab. OBSERVATIONS: A 68-year-old female patient with diabetic macular oedema (DME) from type 2 diabetes mellitus was first diagnosed in October 2010 and had a baseline visual acuity (VA) of 46 Early Treatment Diabetic Retinopathy Study (ETDRS) letters in the left eye...
September 2016: Case Reports in Ophthalmology
https://www.readbyqxmd.com/read/28196056/effect-of-an-intravitreal-dexamethasone-implant-on-diabetic-macular-edema-after-cataract-surgery
#7
Pilar Calvo, Antonio Ferreras, Fadwa Al Adel, Wantanee Dangboon, Michael H Brent
PURPOSE: To analyze the effects of a dexamethasone intravitreal implant (DEX; Ozurdex 700 μg; Allergan) administered immediately after cataract surgery in diabetic patients. METHODS: This prospective, single-arm, open label study (NCT01748487 at ClinicalTrials.gov) involved Type 2 diabetic patients with at least mild diabetic retinopathy (DR) who underwent cataract surgery and DEX insertion after phacoemulsification, and intraocular lens implantation were enrolled...
February 10, 2017: Retina
https://www.readbyqxmd.com/read/28195619/efficacy-of-the-intravitreal-sustained-release-dexamethasone-implant-for-diabetic-macular-edema-refractory-to-anti-vascular-endothelial-growth-factor-therapy-meta-analysis-and-clinical-implications
#8
Zainab Khan, Robin K Kuriakose, Maryam Khan, Eric K Chin, David R P Almeida
BACKGROUND AND OBJECTIVE: To assess the effect on best-corrected visual acuity (BCVA) and efficacy of the intravitreal sustained-release 0.7 mg dexamethasone implant (Ozurdex; Allergan, Irvine, CA) in patients with recalcitrant diabetic macular edema (DME). PATIENTS AND METHODS: Meta-analysis utilizing the MOOSE framework and a random effects model. Studies included adults undergoing treatment with Ozurdex for DME. The methodologic quality of each study was assessed using the MINORS and the Cochrane Collaboration Risk of Bias for randomized studies...
February 1, 2017: Ophthalmic Surgery, Lasers & Imaging Retina
https://www.readbyqxmd.com/read/28185180/primary-iris-claw-iol-retrofixation-with-intravitreal-triamcinolone-acetonide-in-cases-of-inadequate-capsular-support
#9
Aditya Kelkar, Rachana Shah, Viraj Vasavda, Jai Kelkar, Shreekant Kelkar
PURPOSE: To assess the outcomes and analyze complication rates following primary iris claw IOL retrofixation with intravitreal triamcinolone acetonide. METHODS: This is a retrospective interventional case series. Patients with poor capsular support-diagnosed preoperatively or owing to intraoperative complications-were treated with iris claw IOL retrofixation with intravitreal triamcinolone acetonide. The data were retrospectively analyzed. RESULTS: 104 eyes of 102 patients with poor capsular support who underwent the procedure between 2010 and 2013 were analyzed...
February 9, 2017: International Ophthalmology
https://www.readbyqxmd.com/read/28165610/diabetic-macular-edema-outcomes-in-eyes-treated-with-fluocinolone-acetonide-0-2-%C3%A2%C2%B5g-d-intravitreal-implant-real-world-uk-experience
#10
Ibraheem El-Ghrably, David H W Steel, Maged Habib, Daniela Vaideanu-Collins, Sridhar Manvikar, Roxane J Hillier
PURPOSE: To conduct an observational, multicenter study to evaluate real-world clinical efficacy and safety of the 0.2 µg/day fluocinolone acetonide (FAc) implant in the treatment of patients with chronic diabetic macular edema (DME) in 3 large hospital ophthalmology departments in the United Kingdom. METHODS: Fluocinolone acetonide implants were inserted into the study eyes following a suitable washout period; phakic eyes received FAc implant following cataract surgery...
February 6, 2017: European Journal of Ophthalmology
https://www.readbyqxmd.com/read/28106887/report-of-12-months-efficacy-and-safety-of-intravitreal-fluocinalone-acetonide-implant-for-the-treatment-of-chronic-diabetic-macular-oedema-a-real-world-result-in-the-united-kingdom
#11
F Alfaqawi, P L Lip, S Elsherbiny, R Chavan, A Mitra, B Mushtaq
: PurposeTo report the 12-months visual and anatomical outcomes of chronic diabetic macular oedema (DMO) treated with ILUVIEN in a real-world clinical practice in a single tertiary referral centre.MethodRetrospective data collection and analysis of consecutive 28 eyes of 23 diabetic patients received ILUVIEN implant for refractory DMO. Standard assessment included visual acuity (VA), central retinal thickness (CRT), slit-lamp biomicroscopy, and Goldmann tonometry for intraocular pressure (IOP) at 1, 6, and 12 months...
January 20, 2017: Eye
https://www.readbyqxmd.com/read/28098203/optical-coherence-tomography-angiography-microvascular-findings-in-macular-edema-due-to-central-and-branch-retinal-vein-occlusions
#12
Mastropasqua Rodolfo, Toto Lisa, Di Antonio Luca, Borrelli Enrico, Senatore Alfonso, Di Nicola Marta, Di Martino Giuseppe, Ciancaglini Marco, Paolo Carpineto
The aim of this study was to evaluate retinal and choriocapillaris vessel density using optical coherence tomography angiography (OCTA) in eyes with central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO) complicated by macular edema (ME). Sixty eyes of 60 patients with CRVO or BRVO and ME and 40 healthy subjects underwent measurements of superficial and deep foveal and parafoveal vessel density (FVD, PFVD) and choricapillary density using OCTA at baseline and 60 days after intravitreal dexamethasone implant (IVDEX)...
January 18, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28058154/intravitreal-dexamethasone-implant-ozurdex-for-refractory-macular-edema-secondary-to-retinitis-pigmentosa
#13
Nurgül Örnek, Kemal Örnek, İnci Elif Erbahçeci
Macular edema (ME) in retinitis pigmentosa (RP) often impairs central vision dramatically. A 41-year-old woman diagnosed with RP was referred to our outpatient clinic due to severe visual deterioration in both eyes. The patient was treated with topical carbonic anhydrase inhibitors, topical corticosteroids and intravitreal triamcinolone acetonide injections, but her ME recurred. Intravitreal 0.7 mg dexamethasone implant (Ozurdex, Allergan) was administered into both eyes without complications. On the fourth day after both injections, visual acuity improved and ME almost totally resolved...
August 2016: Turkish Journal of Ophthalmology
https://www.readbyqxmd.com/read/28031700/long-term-results-of-combination-therapy-using-anti-vegf-agents-and-dexamethasone-intravitreal-implant-for-retinal-vein-occlusion-an-investigational-case-series
#14
Michael A Singer, Michael E Jansen, Lyndon Tyler, Paul Woods, Faisal Ansari, Udit Jain, Joshua Singer, Darren Bell, Chelsey Krambeer
BACKGROUND: One limitation of anti-VEGF therapy is the need for monthly retreatment to maintain efficacy. The purpose of this study was to determine the duration of effect in eyes with macular edema (ME) secondary to branch or central retinal vein occlusion (BRVO or CRVO) treated with anti-VEGF therapy plus sustained-release dexamethasone (DEX implant; Ozurdex). MATERIALS AND METHODS: This open-label, interventional case series included 62 eyes with ME due to RVO, central foveal thickness (CFT) >300 μm, and best-corrected visual acuity (BCVA) of 20/40 or worse...
2017: Clinical Ophthalmology
https://www.readbyqxmd.com/read/28017484/choroidal-haemangioma-and-photodynamic-therapy-anatomical-and-functional-response-of-patients-with-choroidal-hemangioma-treated-with-photodynamic-therapy
#15
O Subirà, H Brosa, D Lorenzo-Parra, L Arias-Barquet, J Català-Mora, E Cobos, P Garcia-Bru, M J Rubio-Caso, J M Caminal-Mitjana
OBJECTIVE: To study the effectiveness and limitations of photodynamic therapy (PDT) as treatment of choice in patients with symptomatic circumscribed choroidal haemangioma. METHODS: A retrospective study was conducted on 16 patients (13 men and 3 women, with mean age of 54.88 years) with circumscribed choroidal haemangioma, who attended our centre and were treated with PDT in the last 7 years. RESULTS: All patients had circumscribed choroidal haemangioma, which caused a decrease in visual acuity (VA) secondary to the presence of intraretinal microcystic oedema or neurosensory detachment...
December 22, 2016: Archivos de la Sociedad Española de Oftalmología
https://www.readbyqxmd.com/read/28012104/intravitreal-dexamethasone-implant-for-the-treatment-of-cystoid-macular-oedema-associated-with-acute-retinal-necrosis
#16
Parthopratim Dutta Majumder, Jyotirmay Biswas, Asra Ambreen, Rowayda Amin, Zahedur Rahman Pannu, Ahmed Magdy Bedda
BACKGROUND: Acute retinal necrosis is a rare but devastating ocular condition. We report two cases of acute retinal necrosis in immunocompetent patients, complicated by cystoid macular oedema and treated with intravitreal dexamethasone (OZURDEX®) implant. RESULTS: Two patients diagnosed with acute retinal necrosis were treated with intravenous acyclovir. Both of them developed cystoid macular oedema following resolution of viral retinitis. Ocular condition of the first patient was further complicated by central serous chorioretinopathy...
December 2016: Journal of Ophthalmic Inflammation and Infection
https://www.readbyqxmd.com/read/28009415/dexamethasone-intravitreal-implant-at-the-time-of-cataract-surgery-in-eyes-with-diabetic-macular-edema
#17
Giacomo A Panozzo, Elena Gusson, Giorgio Panozzo, Giulia Dalla Mura
PURPOSE: To determine the potential role of intraoperative dexamethasone intravitreal implant (DEX-I) in reducing diabetic macular edema (DME) worsening after phacoemulsification. METHODS: This was a prospective study on 19 eyes of 19 patients with type 2 diabetes mellitus with DME and cataract. Mean preoperative Early Treatment Diabetic Retinopathy Study visual acuity (VA) was 16.7 letters. Mean foveal thickness (FT) was 451 μm. The DME was naive in 11 eyes and refractory in 8 eyes...
December 16, 2016: European Journal of Ophthalmology
https://www.readbyqxmd.com/read/28004156/-intramuscular-depot-steroids-possible-treatment-of-postsurgical-cystoid-macula-edema-with-steroid-response
#18
A-M Seuthe, P Szurman, K T Boden
We report on a patient with postsurgical cystoid macular edema (CME) after phacoemulsification and multifocal intraocular lens (MIOL) implantation. At first, there was a very good reaction to intravitreal triamcinolone, inducing complete regression of the edema without increasing intraocular pressure (IOP). One year later the patient suffered from retinal detachment and was treated with vitrectomy, laser, and gas tamponade. Afterward, he developed macular pucker with edema. After surgical treatment with pucker peeling and intravitreal triamcinolone, the patient showed a steroid response and an increase IOP...
December 21, 2016: Der Ophthalmologe: Zeitschrift der Deutschen Ophthalmologischen Gesellschaft
https://www.readbyqxmd.com/read/27999699/location-of-a-dexamethasone-implant-at-the-macula-after-intravitreal-injection-in-a-silicone-oil-filled-eye
#19
Cenap Mahmut Esenulku, Murat Gunay
Here, we report a case with cystoid macular edema (CME) due to central retinal vein occlusion (CRVO) presented with a dexamethasone implant (Ozurdex) trapped at the macula in her silicone oil- (SO-) filled eye after injection. No additional complications such as intraocular pressure (IOP) rise or retinal damage were observed. The CME was resolved during the follow-up period. At the last visit, 3 months following the injection, Ozurdex implant was found to be mostly dissolved without any additional ocular complications...
2016: Case Reports in Ophthalmological Medicine
https://www.readbyqxmd.com/read/27984545/efficacy-of-dexamethasone-intravitreal-implant-for-refractory-macular-edema-caused-by-retinal-vein-occlusion
#20
Rehan M Hussain, Thomas A Ciulla, Lauren M Ciulla, Bethany Sink, Alon Harris
PURPOSE: To investigate efficacy of dexamethasone intravitreal (DEX) implant in treating refractory macular edema caused by retinal vein occlusion. METHODS: Retrospective chart review. RESULTS: Twenty-two eyes with refractory macular edema caused by retinal vein occlusion were treated with a mean of 2.2 DEX over 12 months. Patient had previously received a mean of 7 treatments (laser, bevacizumab, and/or triamcinolone) for macular edema present for at least 4 months duration (mean 20...
December 14, 2016: Retinal Cases & Brief Reports
keyword
keyword
99632
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"